Pharmaceuticals France

France Plasma-Derived Therapies Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.01 Bn Placeholder estimate
Estimate 2025 $1.07 Bn 2.9% of the global market
Projected 2034 $1.84 Bn 71.8% Adds $767.9 Mn over 9 forecast years
CAGR 2025–2034 6.2% Faster than 41% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.92% of the global market.
  • In Europe, the largest is Germany at $1.49 Bn.
  • Fastest growing: Russia at 6.8% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$767.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Plasma-Derived Therapies Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.01 Bn — —
2025 (base) $1.07 Bn +$62.4 Mn —
2026 (forecast) $1.14 Bn +$66.3 Mn +6.2%
2027 (forecast) $1.21 Bn +$70.4 Mn +12.8%
2028 (forecast) $1.28 Bn +$74.7 Mn +19.8%
2029 (forecast) $1.36 Bn +$79.4 Mn +27.2%
2030 (forecast) $1.44 Bn +$84.3 Mn +35.1%
2031 (forecast) $1.53 Bn +$89.5 Mn +43.5%
2032 (forecast) $1.63 Bn +$95.1 Mn +52.4%
2033 (forecast) $1.73 Bn +$101.0 Mn +61.8%
2034 (forecast) $1.84 Bn +$107.2 Mn +71.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Plasma-Derived Therapies Market Analysis at a glance
Market size, 2025$1.07 Bn placeholder estimate
Forecast, 2034$1.84 Bn placeholder estimate
Growth (CAGR), 2025–20346.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersCSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma, Kedrion Biopharma (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Plasma-Derived Therapies Market Analysis Executive Summary

Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.

Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).

Bar chart: France Plasma-Derived Therapies market size, 2024–2034, placeholder estimates. $1.01 Bn in 2024, $1.07 Bn in 2025 and $1.84 Bn in 2034, 6.2% CAGR.
France Plasma-Derived Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Plasma-Derived Therapies Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.

Competitive Landscape for Plasma-Derived Therapies Market in France

The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Plasma-Derived Therapies Market in France

Plasma-Derived Therapies in France: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Plasma-Derived Therapies in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Plasma-Derived Therapies market in France?
Placeholder estimate: about $1.07 Bn in 2025, rising to about $1.84 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Plasma-Derived Therapies market in France growing?
Placeholder estimate: about 6.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Plasma-Derived Therapies market report cover?
The report splits the market by product (Immunoglobulins, Albumin, Coagulation Factors, Alpha-1 Antitrypsin), application (Immunology, Hematology, Critical Care, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Plasma-Derived Therapies market?
Key players include CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma and Kedrion Biopharma.
What is driving the Plasma-Derived Therapies market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Who regulates Plasma-Derived Therapies in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How much research is published on Plasma-Derived Therapies?
PubMed lists 1,017 papers on Plasma-Derived Therapies added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on biologics and biosimilars

See the topic